Arecor Therapeutics: EASD 2024: Positive Phase I for AT278 in Type II diabetes
Detailed data from the Phase I study in Type II diabetes (T2D) of Arecor’s lead asset AT278, a unique ultra-rapid and ultra-concentrated insulin, were presented at the European Association for the Study of Diabetes (EASD) 2024 meeting. These data confirm its attractive profile, with faster onset and stronger early glucose-lowering effect in comparison to gold standard fast-acting insulin NovoRapid/NovoLog (NovoNordisk). Clinical data to date suggest a pertinent and highly differentiated profile that is suited for T2D patients with high insulin needs, and which could also enable miniaturised ‘next generation’ insulin delivery systems with longer-wear times. Given the data and unmet patient need, an optimal strategy for continued AT278 development is under evaluation by Arecor. This includes plans for a small pump study, alongside consideration of strategic co-development. Following the recent fundraise and trading statement, our reinstated valuation is £157m, or 415p/share.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.